Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AA2D
|
|||
| Former ID |
DAP000877
|
|||
| Drug Name |
Bifonazole
|
|||
| Synonyms |
Amycor; Azolmen; Bifokey; Bifomyk; Bifon; Bifonazol; Bifonazolum; Moldina; Mycospor; Trifonazole; Bayer brand of bifonazole; Bioglan brand of bifonazole; Canesten Extra Bifonazol; Canesten brand of bifonazole; Dermapharm brand of bifonazole; Inkeysa brand of bifonazole; Juventus brand of bifonazole; Merck Lipha Sante brand of bifonazole; Bay H-4502; Bifonazol [INN-Spanish]; Bifonazolum [INN-Latin]; Canespor (TN); Mycospor (TN); Bay-h-4502; Bifonazole (JP15/USAN/INN); Bifonazole [USAN:BAN:INN:JAN]; (+-)-1-([1,1'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole; (+-)-1-(p,alpha-Diphenylbenzyl)imidazole; 1-((4-Biphenylyl)phenylmethyl)-1H-imidazole; 1-(alpha-(4-Biphenylyl)benzyl)imidazole; 1-(p,alpha-Diphenylbenzyl)imidazole; 1-[4,alpha-Diphenylbenzyl]-imidazole; 1-[biphenyl-4-yl(phenyl)methyl]-1H-imidazole; 1-[phenyl-(4-phenylphenyl)methyl]imidazole
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Fungal infection [ICD-11: 1F29-1F2F; ICD-10: B35-B49; ICD-9: 110-118] | Approved | [1] | |
| Therapeutic Class |
Antifungal Agents
|
|||
| Company |
Bayer Pharmaceuticals Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H18N2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4
|
|||
| InChI |
1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H
|
|||
| InChIKey |
OCAPBUJLXMYKEJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 60628-96-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
603868, 855867, 4422038, 7848838, 8151596, 11373018, 11483865, 11487851, 11491785, 12013311, 14874247, 26612889, 26680150, 26719682, 26747221, 26747222, 29221545, 46386787, 46507284, 47359445, 49833729, 49979108, 50105275, 53790254, 56422098, 57321292, 77059268, 81092785, 85084179, 85171922, 85788008, 92124602, 92307859, 92308334, 92309209, 92714230, 99351129, 103179440, 104020311, 104171382, 104300416, 117814570, 124637818, 124658982, 124766210, 124800208, 124883565, 124883566, 124883567, 125354196
|
|||
| ChEBI ID |
CHEBI:78692
|
|||
| SuperDrug ATC ID |
D01AC10
|
|||
| SuperDrug CAS ID |
cas=060628968
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Bifonazole (adjusted p-values: 3.20E-04). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Bifonazole (adjusted p-values: 2.81E-04). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Bifonazole (adjusted p-values: 2.87E-03). | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Bifonazole (adjusted p-values: 3.92E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Bifonazole (adjusted p-values: 4.93E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Erysipelatoclostridium ramosum
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Erysipelatoclostridium ramosum was decreased by Bifonazole (adjusted p-values: 1.03E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Bifonazole (adjusted p-values: 7.48E-07). | |||
|
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridium perfringens was decreased by Bifonazole (adjusted p-values: 1.35E-05). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Bifonazole (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Bifonazole (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Enterocloster bolteae was decreased by Bifonazole (adjusted p-values: 2.10E-03). | |||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Bifonazole (adjusted p-values: 6.79E-06). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Bifonazole (adjusted p-values: 1.65E-04). | |||
|
Studied Microbe: Lacrimispora saccharolytica
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Lacrimispora saccharolytica was decreased by Bifonazole (adjusted p-values: 2.74E-03). | |||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Bifonazole (adjusted p-values: 1.65E-04). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Bifonazole (adjusted p-values: 1.60E-04). | |||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Bifonazole (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus gnavus was decreased by Bifonazole (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Bifonazole (adjusted p-values: 5.45E-05). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Candida Cytochrome P450 51 (Candi ERG11) | Target Info | Inhibitor | [3], [4], [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drug information of Bifonazole, 2008. eduDrugs. | |||
| REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 3 | Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7. | |||
| REF 4 | Bifonazole, a biochemist's view. Dermatologica. 1984;169 Suppl 1:3-9. | |||
| REF 5 | Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole. Arzneimittelforschung. 1984;34(2):139-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.